Donate
Launch of U.S. State Legislative Guide for Insulin for All

Launch of U.S. State Legislative Guide for Insulin for All

Facebook Google LinkedIn Twitter

T1International is pleased to introduce a new advocacy resource, the U.S. Legislative Guide for insulin for all: How States Can Make Medicines Affordable. The resource, developed in partnership with Public Citizen, outlines a variety of legislation that could help to make insulin more accessible and affordable, including:

  • Emergency Insulin Refills (also known as Kevin’s Law)Emergency prescription refill legislation, known in many states as Kevin's Law, allows a pharmacist to use their professional judgement if a doctor cannot be reached to authorize a prescription and dispense an emergency supply of a chronic maintenance drug.
  • Insurance Copay CapsCopay caps set out-of-pocket limits for insulin for those with certain insurance plans. Though these bills are often referred to as “price caps,” they do not cap the price, but the out-of-pocket expense that patients pay at the pharmacy counter. This legislation excludes the uninsured, as well as those that are on insurance plans that are subject to federal regulation.
  • Insulin Assistance ProgramsAn insulin assistance program allows some individuals to receive insulin at participating pharmacies with a nominal co-payment. Minnesota’s Alec Smith Emergency Insulin Act is one example of such legislation.
  • TransparencyTransparency legislation allows states to request detailed information about research and development costs, marketing expenses, pricing strategies and profits for prescription drugs, including insulin. While transparency by itself does not reduce the price of insulin, it gives us a better picture of what is happening behind the scenes.
  • Limiting Price SpikesBy fining companies for raising drug prices beyond inflation, states could help prevent further price-gouging.
  • Drug Affordability BoardsMuch like how they set rates for electricity and water, states can regulate medicine prices to make insulin more affordable. Drug affordability boards would transform the role of states in regulating drug prices by developing an independent body to evaluate and set limits on the prices of medicines.
  • Competitive Licensing RequestsStates can ask the federal government to break patent monopolies and authorize low-cost generic competition. Under the Eleventh Amendment, the state could also explore legal claims about how its sovereignty could protect it from patent infringement claims.
  • Public Production of InsulinStates can produce their own affordable insulin. Public insulin could lower prices and increase access. A not-for-profit, government insulin manufacturer could produce insulin at an affordable price and ensure a reliable supply.

Across the U.S., #insulin4all Chapters and advocates have been instrumental in asking for comprehensive reform to make insulin more accessible. From the Alec Smith Insulin Bill in Minnesota to Kevin’s Law being passed in numerous states, advocates are sharing their stories and building momentum.

For decades, an unspoken truth in Washington and state capitals across the country was that the pharmaceutical industry was untouchable. Now, thanks to patients speaking up and using their voices, things are different. Patient stories have changed hearts and minds, and now they’re starting to change policies so that everyone can access and afford the medicines they need.

This Legislative Guide provides advocates with information on bills that may be possible to pursue in their states. Paired with many of T1International’s other resources, including our Advocacy Toolkit and Guide for Contacting Legislators, it is our hope that this new Legislative Guide resource helps individuals in their fights, and moves the United States closer to making insulin for all a reality.

Related posts:

T1International Statement on Executive Orders

T1International Statement on Executive Orders

On Friday afternoon, President Trump released four executive orders intended to lower drug prices, including two targeted directly at lowering the cost of insulin for patients who rely on it. Despite his assertion that these orders are intended to “completely restructure the prescription drug market,” these orders will not do anything to fix the underlying cause of the insulin crisis in America. Patients will still need to wait months for the rulemaking process to run its course, and likely even longer after that if these orders end up in court. While T1International USA is glad that the administration has stated that making insulin more affordable is a priority, these orders miss the mark. We don’t need incremental bureaucratic steps as an election approaches - we need transformative change that will make our medicine more affordable now. Read more

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International is outraged, though not surprised, to see pharmaceutical companies once again put profit over human lives. On Tuesday, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the state of Minnesota to challenge the Alec Smith Insulin Affordability Act. Read more

Utahns Welcome Passage of Insulin Access Amendments

Utahns Welcome Passage of Insulin Access Amendments

After many emotional months of fighting hard for accessible and affordable insulin legislation, Utah won a victory March 30, 2020 when House Bill 207, known as the Insulin Access Amendments, was signed into law by Governor Gary Herbert. This victory was thanks in part to the strong advocacy of thousands of Utahns and to Representative Norman Thurston’s dedicated leadership on drafting lifesaving legislation. This legislation passed with strong bipartisan support through the House with a 69-3 vote and passed unanimously in the Senate. Read more

How Shareholders Benefit from Insulin Price Increases

How Shareholders Benefit from Insulin Price Increases

In March of this year, researchers at the University of Pittsburgh provided evidence that the net price of insulin medicines in the United States had also soared – by 51% between 2008-2017. This indicates that while other intermediaries had benefited from list price increases, the manufacturers had too. This may seem obvious, but having data to prove it is important. Read more

Advocates Celebrate Passage of Alec Smith Bill in Minnesota

Advocates Celebrate Passage of Alec Smith Bill in Minnesota

After months of diligent advocacy, partisan gridlock, and intense negotiations, the Alec Smith Emergency Insulin Bill was signed into law today in Minnesota. Alec’s Bill is named for 26-year-old Alec Smith, who passed away after rationing his insulin in 2017. The legislation, which is the first of its kind in the nation, establishes a program for patients with diabetes to purchase the insulin they need at an affordable price. To get to this moment, advocates in Minnesota endured a tough - and long - fight. Read more

#insulin4all Workshop & Vigil

#insulin4all Workshop & Vigil

In September 2019, T1International held our first ever two-day #insulin4all workshop for USA Chapters. The purpose of the workshop was to bring Chapter Leaders together and build their skills and advocating power to push for more affordable, accessible insulin and supplies. About 45 people from about 20 Chapters across the USA came to Indianapolis for the workshop, which included a third annual event outside of Eli Lilly taking the form of a vigil to honor lives lost due to rationing. Read more